No. Raloxifene does not act like estrogen in other body parts such as the uterus and breasts and does not cause an increased risk of uterine cancer.
It benefits as an estrogen agonist in bones and lipid metabolism and as an estrogen antagonist in the uterus and breasts without yielding negative effects.